Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Movcol is an osmotic laxative marketed by Genix Pharma, primarily used for the treatment of chronic constipation and fecal impaction. It is a branded generic formulation containing macrogol 3350 (polyethylene glycol) and a balanced blend of electrolytes, including sodium chloride, sodium bicarbonate, and potassium chloride. The macrogol component works by binding water molecules, which increases the volume of intestinal fluid and softens the stool, thereby stimulating colonic propulsive motility. The electrolytes are included to ensure that there is no net gain or loss of water or electrolytes from the body during the laxative process, maintaining systemic balance while facilitating bowel evacuation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on macrogol 3350 + sodium chloride + sodium bicarbonate + potassium chloride (Genix Pharma).